Tomasz Olesiński

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Charles S. Fuchs, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · Gastric Cancer · 2021 · 162 citations · Full text

The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2020 · 54 citations

Pembrolizumab Versus Paclitaxel, Cancer Management, Immunology +18

Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer

Paweł Krawczyk, Tomasz Powrózek, Tomasz Olesiński et al. · International Journal of Colorectal Disease · 2017 · 50 citations · Full text

Mir-4316 Expression, Oncology, Cancer Detection +11

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

Charles S. Fuchs, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2020 · 37 citations

Pembrolizumab Versus Paclitaxel, Cancer Management, Gastroenterology +17